Abrdn Life Sciences Investors (NYSE:HQL) Short Interest Update

Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 49,600 shares, a growth of 100.8% from the January 31st total of 24,700 shares. Based on an average daily volume of 126,000 shares, the short-interest ratio is currently 0.4 days.

Abrdn Life Sciences Investors Stock Performance

HQL stock traded down $0.20 during trading on Monday, hitting $13.25. The company had a trading volume of 171,280 shares, compared to its average volume of 94,844. The firm has a 50-day moving average price of $13.73 and a 200-day moving average price of $14.41. Abrdn Life Sciences Investors has a 12 month low of $12.76 and a 12 month high of $15.90.

Abrdn Life Sciences Investors Cuts Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Friday, February 21st will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 14.19%. The ex-dividend date of this dividend is Friday, February 21st.

Insider Buying and Selling

In related news, major shareholder Saba Capital Management, L.P. sold 15,143 shares of the business's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $14.27, for a total value of $216,090.61. Following the completion of the transaction, the insider now owns 3,381,371 shares in the company, valued at $48,252,164.17. The trade was a 0.45 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders sold 108,386 shares of company stock worth $1,511,590 in the last quarter. Insiders own 10.06% of the company's stock.

Institutional Trading of Abrdn Life Sciences Investors

Several institutional investors and hedge funds have recently made changes to their positions in the business. Ameriprise Financial Inc. raised its position in shares of Abrdn Life Sciences Investors by 7.5% during the 4th quarter. Ameriprise Financial Inc. now owns 153,396 shares of the company's stock valued at $1,999,000 after acquiring an additional 10,742 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Abrdn Life Sciences Investors during the 4th quarter valued at $290,000. Stifel Financial Corp raised its position in shares of Abrdn Life Sciences Investors by 67.1% during the 4th quarter. Stifel Financial Corp now owns 28,341 shares of the company's stock valued at $372,000 after acquiring an additional 11,378 shares during the last quarter. Guggenheim Capital LLC acquired a new position in shares of Abrdn Life Sciences Investors during the 4th quarter worth about $211,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Abrdn Life Sciences Investors in the 4th quarter valued at about $3,129,000. Institutional investors own 32.21% of the company's stock.

Abrdn Life Sciences Investors Company Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.